Fludarabine Based RIC for Bone Marrow Failure Syndromes

Bone Marrow Failure Syndromes Clinical Trial

Official title:

Fludarabine-Based Conditioning for Matched Related Donor Bone Marrow Transplantation in Patients With Bone Marrow Failure Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02928991
• Other study ID #: 14-011465
• Secondary ID: 14BT057
• Status: Recruiting
• Phase: Early Phase 1
• Start date: April 2015
• Est. completion date: December 2026

Study information

• Verified date: June 2024
• Source: Children's Hospital of Philadelphia
• Contact: Megan Atkinson
• Phone: 215-590-2820
• Email: cttsbmtintake[@]chop.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study to determine whether fludarabine-based reduced intensity conditioning (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA) and Inherited bone marrow failure (iBMF) syndromes undergoing Matched related donor bone marrow transplant (MRD-BMT).

Description:

Acquired AA patients will receive the experimental regimen of fludarabine with dose-reduced cyclophosphamide, with results in this prospective single arm experimental group evaluated in the context of our institutional historical experience using HD Cy regimens as well as published outcomes using both fludarabine and high-dose cyclophosphamide-based regimens for MRD-BMT in aplastic anemia. iBMF syndrome patients will receive one of two fludarabine-containing regimens based on disease characteristics, and our outcomes will be compared to previously published data using a variety of regimens. Graft versus host disease (GvHD) prophylaxis will consist of cyclosporine/tacrolimus alone for patients with acquired AA or cyclosporine/tacrolimus plus mycophenolate for patients with iBMF syndromes. For both acquired AA and iBMF syndrome patients, donor chimerism will be assessed at scheduled intervals following BMT and will be used to define patients with full donor or mixed chimerism for comparisons of survival, graft failure, cytogenetic, GvHD, and immune reconstitution outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 2026
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 22 Years

Eligibility

Patients 0-22 years with acquired aplastic anemia or a diagnosed inherited bone marrow failure syndrome, and a fully Human leukocyte antigen (HLA)-matched (10/10) related donor.

Inclusion Criteria:

Patient:

1. Ages 0-22 years at time of enrollment

2. Diseases:

• Patients with severe or very severe acquired AA, defined by:

• Bone marrow biopsy demonstrating cellularity of <25% (at least 2 weeks from last dose of G-CSF), in addition to 2 of the following: absolute neutrophil count (ANC) <500/µL, platelets < 20,000/µL and absolute reticulocytes <40,000/µL

• Negative evaluation for inherited bone marrow failure conditions and negative evaluation for dysplasia or cytogenetic abnormalities associated with myelodysplastic syndromes

• Patients with concurrent paroxysmal nocturnal hemoglobinuria (PNH) clones are eligible, as long as they meet criteria for severe or very severe aplastic anemia as defined above

• Patients with clinically diagnosed and/or genetically proven iBMF syndromes, resulting in chronic red blood cell or platelet-transfusion dependence and/or an absolute neutrophil count <500/µL. These disorders include, but are not limited to:

• Fanconi Anemia

• Dyskeratosis Congenita

• Severe Congenital Neutropenia

• Diamond-Blackfan Anemia

• Congenital Dyserythropoietic/Sideroblastic Anemias

• Congenital Amegakaryocytic Thrombocytopenia

• Shwachman-Diamond Syndrome

3. Lansky or Karnofsky performance >60

4. HLA matched related donor available.

5. No active untreated infection

6. Females of childbearing potential must have negative pregnancy test.

Organ Function:

• Serum creatinine <1.5xupper limit of normal for age Hepatic: Transaminases <5x normal

• Cardiac shortening fraction >27%

• Bilirubin <2.5x normal (unless elevation due to Gilberts disease).

Donor Selection Criteria:

• Donor selection will comply with U.S. Food and Drug Administration's Code of Federal Regulations

• Fully HLA-matched related donor.

• Donor must be at least 6 months of age

• Donor suitable for bone marrow collection and meets eligibility for donation, including fulfilling infectious disease criteria as per SOP, including HIV, Hepatitis B, Hepatitis C Polymerase chain reaction (PCR) negative.

• If subject has confirmed iBMF syndrome, donor must be evaluated for this disorder and testing must be negative

• Children's Hospital of Philadelphia (CHOP) bone marrow transplant (BMT) procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.

• Donor evaluation and collection procedure as per CHOP Standard Operating Procedures (SOP)

Exclusion Criteria:

• Uncontrolled bacterial, viral or fungal infections

• HLA matched related donor unable to donate bone marrow.

• No eligible fully HLA-matched related donor

• Pregnant females

• Patients with a clinical diagnosis of Myelodysplastic syndrome (MDS) defined by combination of bone marrow dysplasia and classic cytogenetic lesion (Monosomy 7, Trisomy 8 eg.), with or without excess blasts.

• Patients with PNH without underlying bone marrow aplasia

Related Conditions & MeSH terms

• Anemia, Aplastic
• Bone Marrow Failure Disorders
• Bone Marrow Failure Syndromes
• Hemoglobinuria, Paroxysmal
• Pancytopenia
• Syndrome

Intervention

Other:
• MRD-BMT with Fludarabine-based RIC for Acquired AA
Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3 Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4 Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2 Bone marrow infusion: Day 0
• MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia
Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3 Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3 Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2 Bone marrow infusion: Day 0
• MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2 Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)*minute Days: -7, -6, -5, -4 Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8 Bone marrow infusion: Day 0

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of graft failure	Combined rate of primary and secondary graft failure. Primary graft failure is defined as no evidence of neutrophil engraftment by day +28 after stem cell infusion. Secondary graft failure is defined as an ANC<100 for >7-10 days after initial engraftment occurs and is confirmed by hypocellular bone marrow biopsy and donor engraftment <20%.	Up to 1 year post transplant
Primary	Time to neutrophil engraftment	The time from the day of transplant until neutrophil engraftment, which is defined as the first day of ANC >500/ul for the first of 3 consecutive days.	Up to 1 year post transplant
Primary	Transplant-related mortality		Up to 100 days post transplant
Secondary	Rate of overall survival		Up to 1 year post transplant
Secondary	Rate of disease free survival		Up to 1 year post transplant